Archives

CX-2043, an EpCAM-Targeting Probody Drug Conjugate, Demonstrates Anti -Tumor Activity with a Favorable Safety Profile in Preclinical Models

Bob Y. Liu, Joel Shen, Wendy Yu, Chaoran Jing, Sharmi Saha, Vangipuram Rangan, Jennifer Richardson, Yimao Liu, Steven Boule, Jacquelynn Lucas, Olga Ab, Stuart Hicks, W. Michael Kavanaugh, Siew Schleyer, Marcia Belvin. Poster presented at the 32nd EORTC-NCI-AACR Symposium, October 24-25, 2020.

Learn More

Harnessing the Power of CytomX’s Probody® Technology to Drug the Undruggable

Alison L. Hannah, MD. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

Utilizing Probody® Technology to Develop Therapeutics to Undruggable Targets

Bob Liu, Ph.D. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

CX-2009, a CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer

Valentina Boni, Howard Burris, Joyce Liu, Alexander Spira, Hendrik-Tobias Arkenau, Mary Josephine Fidler, Lee Rosen, Randy F. Sweis, Nataliya Uboha, Rachel E. Sanborn, Bert O’Neil, James Harding, Patricia LoRusso, Amy Weise, Javier Garcia-Corbacho, Ivan Victoria, Mark Stroh, Rachel Li, Alison Hannah, Ginny Paton, Funda Meric-Bernstam. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Preliminary Clinical Pharmacokinetics and Dose-Response to Support a Phase 2 Dose Selection for CX-2009: A Masked PROBODY Drug Conjugate to CD166

Mark Stroh, Rachel Li, Hong Lu, Russ Wada, Jennifer Richardson, Amy Peterson. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results From a First-in-Human study (PROCLAIM-CX-2029) in Patients With Advanced Cancer

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, Alexander I. Spira. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Development of a Probody Drug Conjugate (PDC) Targeting CD71 for the Treatment of Cancer

Presented at 10th Annual World Antibody Drug Conjugate Conference. London, United Kingdom March 4, 2020
Luc Desnoyers, Ph.D.

Learn More

Preliminary Results of PROCLAIM-CX-2009, a First-in-Human, Dose-Finding Study of the Probody™ Drug Conjugate CX-2009 in Patients With Advanced Solid Tumors

Funda Meric-Bernstam, Valentia Boni, Alexander Spira, Rachel E. Sanborn, Hendrik-Tobias Arkenau, Randy F. Sweis, Howard Burris, Rui Li, Pratigya Gautam, Sreeni Yalamanchili, Matthias Will, Joyce F. Liu, James J. Harding. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia.

Learn More

A Probody™ Drug Conjugate Targeting CD166 (ALCAM) Enhances Preclinical Antitumor Activity of a Probody Therapeutic Targeting PD-1

Erwan Le Scolan, Tiffany Tse, Michael Krimm, Will Garner, Hikmat Assi, Jennifer Razo, Laurie Wong, Kenneth R. Wong, Victoria Singson, Jennifer Leong, Linnea Diep, Jennifer H. Richardson, Siew Schleyer, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia

Learn More

CD166-DM4 Probody™ Drug Conjugate (CX-2009) Treatment of 198 Patient -derived Xenograft Models (PDX) in a Mouse Clinical Trial Format

Bob Y. Liu, Joel Shen, Matthias Will, Sreeni Yalamanchili, Judi Ford-Gordon, Mark Stroh, Jennifer Richardson, Annie Yang-Weaver, Luc R. Desnoyers, Marcia Belvin, W. Michael Kavanaugh, Siew Schleyer. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia.

Learn More